- Home
- ACRE vs TLSI Comparison
ACRE vs TLSI Comparison
Compare ACRE & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRE
- TLSI
- Stock Information
- Founded
- ACRE 2011
- TLSI 2010
- Country
- ACRE United States
- TLSI United States
- Employees
- ACRE N/A
- TLSI N/A
- Industry
- ACRE Real Estate Investment Trusts
- TLSI Medical Specialities
- Sector
- ACRE Real Estate
- TLSI Health Care
- Exchange
- ACRE Nasdaq
- TLSI Nasdaq
- Market Cap
- ACRE 254.1M
- TLSI 244.3M
- IPO Year
- ACRE 2012
- TLSI N/A
- Fundamental
- Price
- ACRE $4.91
- TLSI $4.61
- Analyst Decision
- ACRE Hold
- TLSI Strong Buy
- Analyst Count
- ACRE 5
- TLSI 3
- Target Price
- ACRE $5.08
- TLSI $10.67
- AVG Volume (30 Days)
- ACRE 432.9K
- TLSI 99.4K
- Earning Date
- ACRE 11-07-2025
- TLSI 11-13-2025
- Dividend Yield
- ACRE 12.17%
- TLSI N/A
- EPS Growth
- ACRE N/A
- TLSI N/A
- EPS
- ACRE N/A
- TLSI N/A
- Revenue
- ACRE $87,777,000.00
- TLSI $40,207,000.00
- Revenue This Year
- ACRE N/A
- TLSI $57.25
- Revenue Next Year
- ACRE N/A
- TLSI $54.05
- P/E Ratio
- ACRE N/A
- TLSI N/A
- Revenue Growth
- ACRE 122.65
- TLSI 49.52
- 52 Week Low
- ACRE $3.35
- TLSI $3.42
- 52 Week High
- ACRE $7.49
- TLSI $5.88
- Technical
- Relative Strength Index (RSI)
- ACRE 59.07
- TLSI 47.90
- Support Level
- ACRE $4.33
- TLSI $3.99
- Resistance Level
- ACRE $4.98
- TLSI $4.54
- Average True Range (ATR)
- ACRE 0.18
- TLSI 0.33
- MACD
- ACRE 0.05
- TLSI -0.03
- Stochastic Oscillator
- ACRE 78.95
- TLSI 57.66
About ACRE Ares Commercial Real Estate Corporation
Ares Commercial Real Estate Corp is a specialty finance company and a Real Estate Investment Trust providing commercial real estate loans and related investments. It operates in one segment namely originating and managing a diversified portfolio of CRE debt-related investments. The group recognizes its revenues through the interest income it receives from loans.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.